Javascript er ikke aktivert i din nettleser. Dette er nødvendig for å bruke Oncolex. Kontakt din systemadministrator for å aktivere JavaScript.

Referanser til lungekreft

    Ikke-småcellet lungekarsinom

  1. Gridelli, C., Langer, C., Maione, P., Rossi, A., Schild, S.E. 2007. Lung cancer in the elderly. J Clin Oncol 25:1898-1907.
  2. Vansteenkiste, J. 2006. Second-line therapeutic options in non-small-cell lung cancer. Lung Cancer 54 Suppl 2:S15-18. 
  3. Winton, T., Livingston, R., Johnson, D., Rigas, J., Johnston, M., Butts, C. et al. 2005. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 352:2589-2597.
  4. Shepherd, F.A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E.H., Hirsh, V., Thongprasert, S. et al. 2005. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132.
  5. Rusch, V.W., Giroux, D.J., Kraut, M.J., Crowley, J., Hazuka, M., Winton, T. et al. 2007. Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). J Clin Oncol 25:313-318.
  6. Graham, M.V., Purdy, J.A., Emami, B., Harms, W., Bosch, W., Lockett, M.A., et al. 1999. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 45:323-329.
  7. Giaccone, G. 2005. Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer. J Clin Oncol 23:3235-3242.
  8. Lally, B.E., Zelterman, D., Colasanto, J.M., Haffty, B.G., Detterbeck, F.C., Wilson, L.D. 2006. Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the surveillance, epidemiology, and end results database. J Clin Oncol 24:2998-3006.
  9. Sundstrøm S, Bremnes R, Aasebø U, Aamdal S, Hatlevoll R, Brunsvig P, Johannessen DC, Klepp O, Fayers PM, Kaasa S. Hypofractionated palliativ radiotherapy (17 Gy per two fractions) in advanced non-small-cell lung carsinoma is comparable to standard fractionation for symptom control and survival: a national phase III trail. J Clin Oncol. 2004 Mar 1; 22(5):801–10.
  10. Oxnard G., Binder A., Jänne PA. New targetable oncogenes in non-small-cell lung cancer. J Clin Oncol 2013:31:1097-104.
  11. Småcellet lungekarsinom

  12. Tiseo, M., Ardizzoni, A. 2007. Current status of second-line treatment and novel therapies for small cell lung cancer. J Thorac Oncol 2:764-772.
  13. Blackstock, A.W.,Govindan, R. 2007. Definitive chemoradiation for the treatment of locally advanced non small-cell lung cancer. J Clin Oncol 25:4146-4152.
  14. Turrisi, A.T., 3rd, Kim, K., Blum, R., Sause, W.T., Livingston, R.B., Komaki, R., et al 1999. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 340:265-271.
  15. Auperin, A., Arriagada, R., Pignon, J.P., Le Pechoux, C., Gregor, A., Stephens, R.J., et al. 1999. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med 341:476-484.
  16. Slotman, B., Faivre-Finn, C., Kramer, G., Rankin, E., Snee, M., Hatton, M., et. al. 2007. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med 357:664-672.
  17. Evans, W.K., Shepherd, F.A., Feld, R., Osoba, D., Dang, P., Deboer, G. 1985. VP-16 and cisplatin as first-line therapy for small-cell lung cancer. J Clin Oncol 3:1471-1477.

    Røyking

  18. Helland A., Brustugun O.T. 2009. Lungekreft hos røykere og aldri-røykere. Tidsskr Nor Laegeforen. 129:1859-62. 
  19. Gandini S, Botteri E, Iodice S. Boniol M, Lowenfels A.B, Maisonneuve P, and Boyle, P. Tobacco smoking and cancer: A meta-analysis. Int J Cancer. 2008 Jan 1; 122(1):155–64.
  20. The 21st century hazards of smoking and benefits of stopping: a prospective study of one million women in the UK. Pirie K., Peto R. Reeves GK, Beral V: Million Women Study Collaborators. Lancet. 2013 Jan. 12: 281 (9861): 133-41.
  21. 21st-century hazards of smoking benefits of cessation in the United States. Jha P., Ramasundarahettige C., Landsman V., Rostron B., Thun M., Anderson R.N., McAfee T., Peto R.
  22.  Active and passive smoking in relation to lung cancer incidence in the Women's Health Initiative Observational Study prospective cohort. Wang A., Kubo J., Luo J.,  Desai M., Hedlin H., Henderson M., . Chlebowski R, Tindle H., Chen C., Gomez S., Manson JE., Schwartz A.G., Wactawski-Wende J., Cote M., Patel M.I., Stefanick M.L., Wakelee H.A. Ann Oncol. 2015 Jan:26 (1):221-30.
  23. Lung cancer in never-smokers: a review. Subramanian J., Govindan R.J Clin.Oncol. 2007 Feb 10:25 (5):561-70.

    Stadieinndeling

  24. New pathologic classification of lung cancer: relevance for clinical practice and clinical trials. Travis WD., Brambilla E., Riely GJ., J Clin Oncol. 2013 Mar 10:31 (8): 992-1001
  25. Goldstraw, P., Crowley, J., Chansky, K., Giroux, D.J., Groome, P.A., Rami-Porta, R., et al. 2007. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2:706-714.

    Prognose

  26. Sagerup CM, Småstuen M, Johannesen TB, Helland A, Brustugun OT. Thorax. 2011 Apr;66(4):301-7.

    Diagnostikk/screening

  27. National Lung Screening Trial Research Team, Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM, Sicks JD. 2011. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011 Aug 4;365(5):395-409.
  28. Humphrey LL, Deffebach M, Pappas M, Baumann C, Artis K, Mitchell JP, Zakher B, Fu R, Slatore CG. 2013. Screening for lung cancer with low-dose computed tomography: a systematic review to update the US Preventive services task force recommendation. Ann Intern Med. 2013 Sep 17;159(6):411-20
  29. Kirurgi

  30. Ginsberg, R.J., and Rubinstein, L.V. 1995. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg 60:615-622; discussion 622-613.
  31. Expanding indications for stereotactic radiosurgery in the treatment of brain metastases. Friedman WA. Neurosurgery. 2013 Aug:60 Suppl 1:9-12.
  32. Diverse

  33. Cancer in Norway 2015, Cancer Registry of Norway, Institute of Population-based Research. Oslo, Norway.
  34. Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppfølging av lungekreft. IS-2124 Helsedirektoratet 01-2014.
  35. Years of life lost as a measure of cancer burden on a national level. Brustugun OT., Møller B., Helland A., Br. J. Cancer. 2014 Aug. 26:111 (5): 1014-20.

Prosedyrer i Oncolex kan ikke erstatte faglig veiledning fra kvalifisert veileder. Den som følger prosedyrene har et selvstendig ansvar for at det foreligger nødvendig godkjenning, lisens eller autorisasjon.
Oslo universitetssykehus HF © 2016